Nasdaq · Healthcare
Xencor Inc (XNCR)
As-reported financials and recent SEC filings for Xencor Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$125.6M
Net income
$-91.9M
Net margin
-73.2%
Diluted EPS
$-1.24
ROE
-14.5%
P/E (TTM)
—
Market cap
—
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $125.6M | $110.5M | $174.6M | $164.6M | $275.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $-177.5M | $-178.4M | $-132.4M | $-82.5M | $43.8M |
| Net income | $-91.9M | $-232.6M | $-133.1M | $-55.2M | $82.6M |
| Diluted EPS | $-1.24 | $-3.58 | $-2.20 | $-0.93 | $1.37 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →1442026-06-18
View on EDGAR →8-K2026-06-18
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-15
View on EDGAR →Largest Healthcare peers
Go deeper on XNCR
Search Xencor Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.